Palliative Care in Neurological Diseases

Nair, Sreeja C.

doi:10.1007/978-981-13-3390-3_20

Textbook of Neuroanesthesia and Neurocritical Care 2019

DOI: 10.1007/978-981-13-3390-3_20

|View full text |Cite

Palliative Care in Neurological Diseases

Sreeja C. Nair

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neuromuscular diseases include a large number of different medical conditions that affect the peripheral nervous system and muscle [ 1 , 2 ]. Many of them are incurable genetic diseases [ 3 , 4 ]. In the last few decades, numerous genes have been identified that directly or indirectly affect neuromuscular function [ 5 ].…”

mentioning

confidence: 99%

Molecular Diagnosis and Novel Therapies for Neuromuscular Diseases

Maruyama

Yokota

2020

JPM

View full text Add to dashboard Cite

With the development of novel targeted therapies, including exon skipping/inclusion and gene replacement therapy, the field of neuromuscular diseases has drastically changed in the last several years. Until 2016, there had been no FDA-approved drugs to treat Duchenne muscular dystrophy (DMD), the most common muscular dystrophy. However, several new personalized therapies, including antisense oligonucleotides eteplirsen for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years. We are witnessing the start of a therapeutic revolution in neuromuscular diseases. However, the studies also made clear that these therapies are still far from a cure. Personalized genetic medicine for neuromuscular diseases faces several key challenges, including the difficulty of obtaining appropriate cell and animal models and limited its applicability. This Special Issue “Molecular Diagnosis and Novel Therapies for Neuromuscular/Musculoskeletal Diseases” highlights key areas of research progress that improve our understanding and the therapeutic outcomes of neuromuscular diseases in the personalized medicine era.

show abstract

mentioning

confidence: 99%

Molecular Diagnosis and Novel Therapies for Neuromuscular Diseases

Maruyama

Yokota

2020

JPM

View full text Add to dashboard Cite

show abstract

Palliative care of patients with Parkinson's disease

Aranđelović,

Simić,

Bogdanović-Vasić

et al. 2023

PONS

View full text Add to dashboard Cite

Parkinson's disease is a progressive neurodegenerative disease that most often affects elderly people. The disease is characterized by a wide range of symptoms, motor (tremor, bradykinesia, postural instability and rigidity) and non-motor (neurological and psychiatric disorders, sleep problems, disorders of the autonomic nervous system, etc.), which as the disease progresses lead to significant disability, dependence in performing daily activities activities and impaired quality of life. Given that there is no therapy that could cure, slow down or stop the further development of the disease, it is necessary to include palliative care and a multidisciplinary team in the treatment of patients. A palliative approach includes recognition of the palliative needs of patients at all stages of the disease, compassion for diagnosis and prognosis, treatment of motor and non-motor symptoms, as well as social, emotional and spiritual aspects, preservation of autonomy, advance care planning and family support. Control of symptoms in Parkinson's disease is carried out by pharmacological treatment, application of complementary non-pharmacological methods and alternative therapy (music, dance, tai chi, massage therapy, application of acupuncture, homeopathy). Also, deep brain stimulation can treat certain symptoms. Treatment varies according to the stage of the disease. Due to the natural course of the disease, individual needs may vary between patients, and for this reason the selection of members of the multidisciplinary team should be based on the needs of each individual. With palliative care with a holistic approach and the involvement of a multidisciplinary team, most symptoms can be controlled. In this way, support can be given to caregivers, which significantly contributes to a better quality of life for both patients and their families, i.e. caregivers.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Palliative Care in Neurological Diseases

Cited by 2 publications

References 52 publications

Molecular Diagnosis and Novel Therapies for Neuromuscular Diseases

Molecular Diagnosis and Novel Therapies for Neuromuscular Diseases

Palliative care of patients with Parkinson's disease

Contact Info

Product

Resources

About